Slow-releasing injection contg. platinum compounds and its potentiator type anticarcinogen
A technology for sustained-release injections and anti-cancer drugs, applied in the fields of sustained-release injections and sustained-release implants, compound anti-cancer drug sustained-release preparations, compound anti-cancer drug sustained-release injections, and can solve the problem of enhanced anti-cancer drug tolerance , treatment failure, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0139] Put 80mg of polyphenylpropane (p-CPP: 20:80 of sebacic acid (SA)) copolymer into a container, add 100ml of dichloromethane, dissolve and mix well, then add 10mg Epplatin and 7-hydroxyl-staurosporine, re-shake and spray-dry to prepare microspheres for injection containing 10% eplatin and 10% 7-hydroxyl-staurosporine. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection. The drug release time of the slow-release injection in physiological saline in vitro is 10-15 days, and the drug release time in mice subcutaneous is about 20-30 days.
Embodiment 2
[0141] The method step of being processed into sustained-release injection is the same as in Example 1, but the difference is that the contained anticancer active ingredients and their weight percentages are:
[0142] (1) 1-40% of cisplatin, bicycloplatin, eberplatin, meciplatin, cisplatin or picoplatin;
[0143] (2) 1-40% of sulfoplatin, bicycloplatin, eplatin, meciplatin, cisplatin or picoplatin and 1-40% of 7-hydroxyl-staurosporine, 7-O-alkyl - combinations of staurosporine, beta-methoxystaurosporine, alkylphosphocholine or hexadecylphosphocholine;
[0144] (3) 1-40% of sulfoplatin, bicycloplatin, eplatin, meciplatin, siciplatin or picoplatin and 1-40% of O4-benzyl folic acid, 2,4,5-triamino-6- Benzyloxypyrimidine, 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine, 2,4-diamino-6-benzyloxy-5-bromopyrimidine, 2-amino-4- Benzyloxy-5-nitropyrimidine, 2-amino-4-benzyloxy-6-methyl-5-nitropyrimidine, 2,4-diamino-6-benzyloxy-s-triazine or 2 - a combination of amino-O4-benzylpteridine;...
Embodiment 3
[0148] Put 70 mg of polylactic acid (PLGA, 75:25) with a peak molecular weight of 65,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, then add 15 mg of Siciplatin and 15 mg of 7-ethyl-10-hydroxycamptothecin , shake again and dry in vacuo to remove the organic solvent. The dried drug-containing solid composition is frozen and pulverized to make micropowder containing 15% cisciplatin and 15% 7-ethyl-10-hydroxycamptothecin, and then suspended in a physiological solution containing 1.5% sodium carboxymethylcellulose. In saline, the corresponding suspension-type sustained-release injection was prepared. The drug release time of the slow-release injection in physiological saline in vitro is 20-35 days, and the drug release time in mice subcutaneous is about 35-50 days.
PUM
Property | Measurement | Unit |
---|---|---|
glass transition temperature | aaaaa | aaaaa |
melting point | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com